

Title (en)

METHODS FOR TREATMENT OF CANCER WITH AN ANTI-TIGIT ANTAGONIST ANTIBODY

Title (de)

METHODEN ZUR BEHANDLUNG VON KREBS MIT EINEM ANTITIGIT-ANTAGONISTISCHEN ANTIKÖRPER

Title (fr)

MÉTHODES DE TRAITEMENT DU CANCER AU MOYEN D'UN ANTICORPS ANTAGONISTE ANTI-TIGIT

Publication

**EP 4096646 A1 20221207 (EN)**

Application

**EP 21705841 A 20210126**

Priority

- US 202062966448 P 20200127
- US 202062985822 P 20200305
- US 202062994272 P 20200324
- US 2020024526 W 20200324
- US 202063059054 P 20200730
- US 202063059960 P 20200731
- US 2020049415 W 20200904
- US 202063074807 P 20200904
- US 202063074827 P 20200904
- US 202063085890 P 20200930
- US 202063105198 P 20201023
- US 202063114517 P 20201116
- US 202063124693 P 20201211
- US 202063127109 P 20201217
- US 2021015143 W 20210126

Abstract (en)

[origin: WO2021154761A1] The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.

IPC 8 full level

**A61K 31/00** (2006.01); **A61K 31/136** (2006.01); **A61K 31/337** (2006.01); **A61K 31/473** (2006.01); **A61K 31/519** (2006.01); **A61K 31/555** (2006.01); **A61K 31/704** (2006.01); **A61K 31/7068** (2006.01); **A61K 33/243** (2019.01); **A61K 39/395** (2006.01); **A61K 45/06** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP IL KR)

**A61K 31/337** (2013.01 - EP IL KR); **A61K 31/365** (2013.01 - KR); **A61K 31/555** (2013.01 - KR); **A61K 31/7068** (2013.01 - KR); **A61K 33/243** (2018.12 - EP IL KR); **A61K 39/395** (2013.01 - EP IL KR); **A61K 45/06** (2013.01 - EP IL KR); **A61P 35/00** (2017.12 - EP IL KR); **C07K 16/2803** (2013.01 - EP IL KR); **C07K 16/2827** (2013.01 - EP IL KR); **A61K 2039/505** (2013.01 - EP IL KR); **A61K 2039/507** (2013.01 - EP IL KR); **A61K 2039/54** (2013.01 - EP IL KR); **A61K 2039/545** (2013.01 - EP IL KR); **A61K 2300/00** (2013.01 - IL KR); **C07K 2317/90** (2013.01 - EP IL KR)

Citation (search report)

See references of WO 2021154761A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

**WO 2021154761 A1 20210805**; AU 2021212662 A1 20220811; CA 3165187 A1 20210805; CN 115315256 A 20221108; EP 4096646 A1 20221207; IL 294800 A 20220901; JP 2023511595 A 20230320; KR 20220133243 A 20221004; MX 2022009170 A 20220817; TW 202142230 A 20211116

DOCDB simple family (application)

**US 2021015143 W 20210126**; AU 2021212662 A 20210126; CA 3165187 A 20210126; CN 202180022830 A 20210126; EP 21705841 A 20210126; IL 29480022 A 20220717; JP 2022545057 A 20210126; KR 20227029306 A 20210126; MX 2022009170 A 20210126; TW 110102913 A 20210126